A limit of 6–8 cycles of pola 1.8 mg/kg has been determined to be effective reducing the risk of peripheral neuropathy (a known adverse event [AE] with pola as a single agent) [45]. The gene discussed is POLA1; the disease is peripheral neuropathy.